Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C S Crumpacker

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Infectious Diseases|September 18, 1997
The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levelsB J Dezube, M M Lederman, B Chapman, et al.
Annals of Internal Medicine|September 1, 1986
Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typingsD E Craven, Z L Awdeh, L M Kunches, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolatesJ J McSharry, N S Lurain, G L Drusano, et al.
JAMA|August 23, 1985
Absence of antibodies to HTLV-III in health workers after hepatitis B vaccinationJ L Dienstag, B G Werner, M F McLane, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
The Journal of Infectious Diseases|July 1, 1982
Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycolS L Spruance, L E Schnipper, J C Overall, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Virology|May 28, 1998
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entryJ L Zhang, H Choe, B J Dezube, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1996
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSH H Balfour, C V Fletcher, A Erice, et al.
The Journal of Infectious Diseases|October 1, 1996
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working GroupsR W Coombs, S L Welles, C Hooper, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Infectious Diseases|September 18, 1997
The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levelsB J Dezube, M M Lederman, B Chapman, et al.
Annals of Internal Medicine|September 1, 1986
Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typingsD E Craven, Z L Awdeh, L M Kunches, et al.
Antimicrobial Agents and Chemotherapy|September 16, 1998
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolatesJ J McSharry, N S Lurain, G L Drusano, et al.
JAMA|August 23, 1985
Absence of antibodies to HTLV-III in health workers after hepatitis B vaccinationJ L Dienstag, B G Werner, M F McLane, et al.
The Journal of Infectious Diseases|May 1, 1995
Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working GroupA J Japour, S Welles, R T D'Aquila, et al.
The Journal of Infectious Diseases|July 1, 1982
Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycolS L Spruance, L E Schnipper, J C Overall, et al.
Annals of Internal Medicine|March 15, 1995
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working GroupR T D'Aquila, V A Johnson, S L Welles, et al.
Virology|May 28, 1998
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entryJ L Zhang, H Choe, B J Dezube, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1996
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDSH H Balfour, C V Fletcher, A Erice, et al.
The Journal of Infectious Diseases|October 1, 1996
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working GroupsR W Coombs, S L Welles, C Hooper, et al.
Pageof 9